AngioDynamics Action

AngioDynamics Conversion FCF

Taux de Conversion FCL (FCL/EBITDA) de AngioDynamics (ANGO) au 22 juil. 2026 est 42,93 %. L'année précédente, Taux de Conversion FCL (FCL/EBITDA) était 18,40 % — une variation de 133,26 % (plus élevé).

Conversion FCF

42,93 %

YoY

133,26%

Dernière mise à jour:

Taux de Conversion FCL (FCL/EBITDA) de AngioDynamics est 2026 42,93 % . Taux de Conversion FCL (FCL/EBITDA) de AngioDynamics était 2025 18,40 % . Elle diminue ainsi de 133,26% plus élevé par rapport à l'année précédente.
Access this data via the Eulerpool API

AngioDynamics Analyse d'actions

Que fait AngioDynamics ? AngioDynamics Inc is a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company was founded in 1988 and is headquartered in Latham, New York. Over the years, AngioDynamics has evolved into a conglomerate through several acquisitions and partnerships, specializing in various areas. The key divisions include Vascular Access Solutions, Oncology Solutions, and Peripheral Vascular Solutions. AngioDynamics' focus is on developing and manufacturing innovative technologies that improve medical care and promote patient health. The company develops and distributes a wide range of medical devices and procedures to treat diseases such as cancer, venous diseases, and thrombosis. In the field of Vascular Access Solutions, AngioDynamics offers a wide range of devices for establishing vascular access, which are necessary in the treatment of serious illnesses. These include port systems and catheters that facilitate access to the body's vascular system. AngioDynamics' Oncology Solutions provide targeted cancer treatment solutions, including ultrasound-guided radiofrequency ablation systems and fusion biopsy systems. Developing innovative diagnostic and treatment options is a key focus of AngioDynamics. A large portion of AngioDynamics' products are in the area of Peripheral Vascular Solutions. Here, the company develops devices and procedures for the treatment of peripheral vascular diseases, such as varicosis or chronic venous insufficiency. This includes minimally invasive procedures such as laser and radiofrequency treatments. Due to its high-quality products, innovative technologies, and close collaboration with medical professionals, AngioDynamics has gained an excellent reputation in the medical industry. The company places great importance on providing optimal care to every patient and therefore serves hospitals, clinics, and medical practices worldwide. Throughout its years of existence, AngioDynamics has become a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company has built a broad customer base worldwide and has become an important player in the medical industry due to the quality and innovation of its products. AngioDynamics est l'une des entreprises les plus populaires sur Eulerpool.

Questions fréquemment posées sur l'action AngioDynamics

Taux de Conversion FCL (FCL/EBITDA) de AngioDynamics s'élève à 42,93 % en 2026.

Access this data via the Eulerpool API

Flux de trésorerie — AngioDynamics

Toutes les Métriques Clés — AngioDynamics

Croissance